Novo Nordisk has announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France.
Novo Nordisk will launch its hugely popular anti-obesity drug in Japan on February 22, its first launch in Asia, even as it struggles to keep up with demand in existing markets.
The rise in diabetic neuropathy over the last few decades has paralleled the obesity and related diabetes pandemics, one expert says, and neurologists have a role to play in controlling it.